Results 241 to 250 of about 264,642 (338)

Cordycepin Targets HRD1 to Promote Cancer Cell PD-L1 Ubiquitin-Proteasome Degradation and Increase Antitumor Immunity. [PDF]

MedComm (2020)
Geng X, Cai M, Hu H, Xu M, Zhang Q, Xu H, Yu D, Zhang H, Xu H, Li L, Guo M, Xie S, Wang Q, Zhang W, Liu S.   +14 more
europepmc   +1 more source

Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides

, 2011
Kanchan Kantekure, Yusong Yang, Puthiyaveettil N. Raghunath, András Schaffer, Anders Woetmann, Qian Zhang, Niels Ødum, Mariusz A. Wasik   +7 more
openalex   +1 more source

PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1); epidermal growth factor receptor (EGFR) [PDF]

, 2013

openalex   +1 more source

Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
Soluble GRP78 (sGRP78) is identified as a novel tumor‐derived soluble factor that induces regulatory T cells (Treg). sGRP78 serves as an excellent serological biomarker for predicting the efficacy of neoadjuvant therapy in breast cancer patients. sGRP78 specifically binds to B cells, inducing the expression of IL‐10 and PD‐L1, thereby promoting Treg ...
Zhenghao Wu, Peng Zheng, Yunxiao Xiao, Qianheng Wang, Xin Pan, Xiaoqi Zhou, Yibing Lv, Junyi Xiao, Yong He, Tao Huang, Ping Lei   +10 more
wiley   +1 more source

Secreted AZGP1 induced by 5-FU binds to PD-L1 and promotes apoptosis in cholangiocarcinoma. [PDF]

Mol Med
You JE, Kim DY, Yun H, Koh DI, Ryu YS, Jin DH.   +5 more
europepmc   +1 more source

PD-L1–Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice [PDF]

, 2014
Rongying Li, Jeongkyung Lee, Mi Sun Kim, Victoria Liu, Mousumi Moulik, Haiyan Li, Qing Yi, Aini Xie, Wenhao Chen, Lina Yang, Yimin Li, Tsung Huang Tsai, Kazuhiro Oka, Lawrence Chan, Vijay Yechoor   +14 more
openalex   +1 more source

Targeted Enrichment of Engineered Bacteria on Triple‐Negative Breast Cancer Turns Immunologically Cold Tumors Hot

Advanced Science, EarlyView.
In this study, an “all‐in‐one” engineered anaerobic bacterial system (PDAEcN/COS) is developed for the treatment of immunologically “cold” TNBC. This nanoplatform is capable of colonizing tumor cell surfaces and implementing “self‐blocking” of immune checkpoints, while simultaneously suppressing tumor cells' “don't eat me” signals and delivering “eat ...
Xuanxiang Zhai, Xiaoyi Shi, Xiao Liu, Xiaotong Gu, Wenting Li, Xiangjun Chen, Wei Hong   +6 more
wiley   +1 more source

Correlation between KAT6A and PD-L1 expression and role of KAT6A in colorectal cancer. [PDF]

World J Gastrointest Oncol
Zhou ZD, Zhao JP, Zheng SC, Wang TT.
europepmc   +1 more source

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

, 2012
Michael R. Green, Scott J. Rodig, Przemysław Juszczyński, Jing Ouyang, Papiya Sinha, Evan A. O’Donnell, Donna Neuberg, Margaret A. Shipp   +7 more
openalex   +1 more source

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model [PDF]

, 2014
Amanda J. Lyon, John T. Fallon, Benjamin Boyerinas, Robert L. Schmitz, Kenneth W. Hance, Yan Lan, Helen Sabzevari, Kwong Y. Tsang, Jeffrey Schlom, John W. Greiner   +9 more
openalex   +1 more source